Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;174(5):687-690.
doi: 10.7326/M21-0111. Epub 2021 Jan 19.

SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn

Mark Connors  1 , Barney S Graham  2 , H Clifford Lane  1 , Anthony S Fauci  1
Affiliations

SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn

Mark Connors et al. Ann Intern Med. 2021 May.

Abstract

As COVID vaccines roll out, internists and other health care providers are being turned to as trusted sources of information for patients and communities. Here, experts from NIAID outline the current state of knowledge regarding such vaccines. They contrast vaccine platforms, summarize clinical trial data regarding efficacy and safety, and comment on key questions including the ability of current vaccines to protect against infection and to decrease the prevalence of virus in the community.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-0111.

Figures

Figure.
Figure.. Cumulative incidence curves for the first COVID-19 occurrence after the first dose of mRNA vaccine.
A. Pfizer-BioNTech vaccine (BNT162b2). Figure reproduced from reference 2 (www.fda.gov/media/144245/download). B. Moderna vaccine (mRNA-1273). Individual severe COVID-19 data similar to those displayed in panel A are not publicly available. Figure reproduced from reference 4 (www.fda.gov/media/144434/download).
See this image and copyright information in PMC

References

    1. Polack FP , Thomas SJ , Kitchin N , et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603-2615. [PMID: ] doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Vaccines and Related Biological Products Advisory Committee Meeting, FDA Briefing Document: Pfizer-BioNTech COVID-19 Vaccine. U.S. Food and Drug Adminstration; 10 December 2020. Accessed at www.fda.gov/media/144245/download on 8 January 2021.
    1. Baden LR , El Sahly HM , Essink B , et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020. [PMID: ] doi:10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Vaccines and Related Biological Products Advisory Committee Meeting, FDA Briefing Document: Moderna COVID-19 Vaccine. U.S. Food and Drug Administration; 17 December 2020. Accessed at www.fda.gov/media/144434/download on 8 January 2021.
    1. Sadoff J , Le Gars M , Shukarev G , et al. Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine. N Engl J Med. 2021. [PMID: ] doi:10.1056/NEJMoa2034201 - DOI - PMC - PubMed